| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenues | 0 | 0 | 0 | 0 |
| Research and development | 5,378,000 | 5,118,000 | 3,738,000 | 3,600,000 |
| General and administrative | 2,488,000 | 2,407,000 | 2,147,000 | 2,091,000 |
| Depreciation and amortization | 8,000 | 9,000 | 21,000 | 29,000 |
| Total operating expenses | 7,874,000 | 7,534,000 | 5,906,000 | 5,720,000 |
| Loss from operations | -7,874,000 | -7,534,000 | -5,906,000 | -5,720,000 |
| Gain from change in fair value of warrant liability | -10,770,000 | -4,187,000 | -1,591,000 | -9,609,000 |
| Transaction costs allocated to warrant liabilities | 693,000 | -2,118,000 | 530,000 | 1,207,000 |
| Loss on extinguishment of warrant liabilities | NaN | -614,000 | NaN | NaN |
| Gain on issuance of warrant liabilities | -15,158,000 | 7,797,000 | -20,609,000 | -10,352,000 |
| Other income, net | 76,000 | -49,000 | 16,000 | 4,000 |
| Interest income, net | 34,000 | 10,000 | 39,000 | 26,000 |
| Net gain | -12,845,000 | 5,915,000 | -25,399,000 | -7,640,000 |
| Foreign currency translation | NaN | NaN | -6,000 | 0 |
| Warrant deemed dividend | 1,765,000 | 101,000 | NaN | NaN |
| Comprehensive loss | NaN | NaN | -25,405,000 | -7,640,000 |
| Net loss available to common stockholders | -14,610,000 | 5,814,000 | NaN | NaN |
| Basic EPS | -3.54 | 4.908 | -0.68 | -0.49 |
| Basic Average Shares | 4,124,482 | 1,184,569* | 37,304,455 | 15,526,401 |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)